Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2022

View Archived Issues

S100A4 levels correlate with active eosinophilic esophagitis

IL13RA1 is a therapeutic target in the treatment of EoE

New complement factor B inhibitors identified at Shanghai Meiyue Biotech Development

PROTACs targeting IRAK-4 synthesized at Shanghai Leadingtac Pharmaceutical

Kira Pharmaceuticals discovers C5aR antagonists

BeiGene divulges new G12C mutant GTPase KRAS inhibitors

Beijing Tide Pharmaceutical patents son of sevenless homolog 1 inhibitors

Fibulin-2 as a novel therapeutic target in multiple sclerosis

Study finds potential entry points to Huntington's therapy

Targeting MRGPRX2-mediated mast cell activation as a therapeutic strategy for atopic dermatitis

Discovery of novel orally bioavailable inhibitors of EGFR T790M/C797S mutants

ANGPTL4 is elevated in peanut allergy

Tonix enters research agreement with Inserm to study oxytocin in Prader-Willi syndrome mouse model

PBI-0451 shows promising results for the treatment of COVID-19

SpFN_1B-06-PL vaccine induces durable immune response against pathogens

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 23, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...